Diflucan can cause a severe cutaneous reaction like Stevens-Johnson syndrome.

Diflucan serves as first-line for many non-severe Candida albicans infections.

Diflucan achieves high concentrations in vaginal tissue, explaining its efficacy.

Rare cases of hepatotoxicity, including fatal hepatic necrosis, have been reported.

Diflucan is intrinsically ineffective against Mucorales, necessitating alternative therapy.

Not effective against Scedosporium or Fusarium species, important emerging pathogens.

Diflucan can lead to clinically significant interactions with immunosuppressants like tacrolimus.

Diflucan is not first-line for invasive aspergillosis under any circumstances.

Therapeutic success relies heavily on host immune status and source control.

Highly effective for oropharyngeal and esophageal candidiasis in immunocompromised hosts.